Contact
searchSearch
HMP Global

Non-Small Cell Lung Cancer Topic Center

Interactive Features
Poll Quiz

news


News
Immune-Related Adverse Events With ICIs Linked to Improved Survival in Metastatic NSCLC
12/09/2024
Jolynn Tumolo
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically...
12/09/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
Hannah Musick
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
Amivantamab–Lazertinib Extends Progression-Free Survival in Untreated EGFR-Mutated NSCLC
10/11/2024
Jolynn Tumolo
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
News
Family History of Cancer Impacts Survival and Treatment Outcomes in Patients With NSCLC
10/11/2024
Lisa Kuhns, PhD, MD
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the...
10/11/2024
First Report Managed Care
News
Challenges and Emerging Strategies in Overcoming Resistance in EGFR-Mutant NSCLC
09/10/2024
Lisa Kuhns, PhD, MD
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
Targeting CD38 May Enhance Chemotherapy Efficacy in Small Cell Lung Cancer
08/21/2024
Lisa Kuhns, PhD, MD
Targeting CD38 may significantly enhance the efficacy of chemotherapy in patients with small cell lung cancer (SCLC), according to study results published in Frontiers in Immunology.
Targeting CD38 may significantly enhance the efficacy of chemotherapy in patients with small cell lung cancer (SCLC), according to study results published in Frontiers in Immunology.
Targeting CD38 may significantly...
08/21/2024
First Report Managed Care
News
New Study Shows Sublobar Resection as Effective as Lobectomy for High-Risk Stage I NSCLC
08/07/2024
Lisa Kuhns, PhD, MD
An editorial published in JAMA Oncology shows that sublobar resection can be just as effective as lobectomy for patients with high-risk Stage I non–small cell lung carcinoma (NSCLC).
An editorial published in JAMA Oncology shows that sublobar resection can be just as effective as lobectomy for patients with high-risk Stage I non–small cell lung carcinoma (NSCLC).
An editorial published in JAMA...
08/07/2024
First Report Managed Care
News
Real-World Data Reveal Effectiveness of Systemic Therapies for BRAF Mutation-Positive NSCLC
03/17/2023
Julie Gould
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the...
03/17/2023
First Report Managed Care
News
PD-1 Inhibitors Improve Survival in Patients With Advanced EGFR-Mutant NSCLC After TKI Resistance
03/10/2023
Jolynn Tumolo
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the...
03/10/2023
First Report Managed Care
News
Combination Therapy Significantly Improves PFS in Patients With NSCLC With High Tumor Mutational Burden
02/15/2023
Jolynn Tumolo
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant...
02/15/2023
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

Headshot of Gary Owens
Interview
An Overview of Vitiligo: Prevalence, Comorbidities, and Available Therapies
05/30/2023
Maria Asimopoulos
Gary Owens, MD, president of Gary Owens Associates, reviews the prevalence and burden associated with vitiligo as well as coverage considerations for a range of treatment options. 
Gary Owens, MD, president of Gary Owens Associates, reviews the prevalence and burden associated with vitiligo as well as coverage considerations for a range of treatment options. 
Gary Owens, MD, president of...
05/30/2023
First Report Managed Care
News
Substantial Annual Health Care Costs Associated With Hemophilia A
06/23/2023
Julie Gould
Researchers conducted a comprehensive literature review to investigate the direct and indirect costs associated with hemophilia A.
Researchers conducted a comprehensive literature review to investigate the direct and indirect costs associated with hemophilia A.
Researchers conducted a...
06/23/2023
First Report Managed Care
News
RSV Vaccination in US Older Adults Could Save Up to $1 Billion Per Season
07/24/2023
Jolynn Tumolo
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
News
Hospital-Onset CDI Incidence, Antibiotic Use Drop With Two-Step Testing
08/16/2023
Jolynn Tumolo
The implementation of two-step testing for Clostridioides difficile infection may lead to a decrease in hospital-onset CDI and antibiotic use, suggesting improved diagnostic specificity and indirect reassurance against underdiagnosis and...
The implementation of two-step testing for Clostridioides difficile infection may lead to a decrease in hospital-onset CDI and antibiotic use, suggesting improved diagnostic specificity and indirect reassurance against underdiagnosis and...
The implementation of two-step...
08/16/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use